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T
his is the fourth of four articles sum-
marizing presentations at the sev-
enth World Congress on the Insulin
Resistance Syndrome, held in San Fran-
cisco,California,on5–7November2009.
This installment pertains to insulin resis-
tance (IR) mechanisms, the brain, and IR
in youth and in the polycystic ovary syn-
drome (PCOS).
Hyperinsulinemia and insulin
secretion abnormalities
Hyperinsulinemia causing IR. Jesse
Roth (New York, NY) suggested that,
rather than IR, hyperinsulinemia should
be considered the major mediator of ad-
verse outcome, with hyperinsulinemia
the underlying characteristic of all syn-
dromes of IR (1). Recalling Edgar Allan
Poe’s story “The Purloined Letter,” Roth
argued that the mediator of IR is insulin,
which is “hidden in plain sight,” causing
hormone-induced inhibition of hormone
action. Similar phenomena are seen in
choriocarcinoma, in which enormous
amounts of human chorionic gonadotro-
pin have no biological effect, in the diver-
gencebetweentheeffectofgonadotropin-
releasing hormone, which enhances
fertility when given in a pulsatile fashion,
whilewhenadministeredcontinuously,it
halts precocious puberty, or between the
effect of parathormone given continu-
ously, causing bone resorption, while
bolus administration increases bone for-
mation. High levels of insulin similarly
decrease the effectiveness of insulin, and
mice overexpressing the insulin gene,
with doubling and quadrupling insulin
levels, fail to show change in weight or
fasting glucose, while developing IR,
postprandial hyperglycemia, and de-
creased insulin receptor binding. Similar
effects of hyperinsulinemia may be dem-
onstrated in normal rats that are given in-
creasingdailydosesofinsulinorthathave
hypothalamic damage, whereas ob/ob
mice that are given alloxan or streptozo-
tocin show improvement in insulin sensi-
tivity. In humans, the Somogyi effect is of
decreasinginsulindosesimprovingglyce-
mia, whereas patients with insulinoma
develop IR, and pulsatile administration
inamannermimickingitsphysiologicre-
lease appears to have greater biologic ef-
fect than that of continuous infusion of a
considerably greater amount of insulin
(2). Basal insulin levels are twice as great
in type 2 diabetic as in normal persons,
despite fairly marked fasting hyperglyce-
mia,sothatalthoughpostloadinsulinlev-
els are decreased, Roth argued that IR,
rather than deﬁciency, mediates the hy-
perglycemia of type 2 diabetes, with IR
potentially mediating defects in insulin
secretion, as insulin receptor activation
appears to be required for -cell glucose
recognition. Presumably, Roth argued,
other insulin responsive tissues such as
the brain and the macrophage also de-
velop IR as a function of hyperinsulin-
emia, leading to “unbalanced” effects
fromonetissuetothenext.Awidevariety
of treatments including exercise, diet,
metformin, acarbose, and thiazo-
lidinediones reduce basal insulin levels
and are associated with improvement in
metabolic proﬁle, whereas, at 20-year
follow-up, basal hyperinsulinemia is the
best predictor of subsequent diabetes (3),
taking into account measures of obesity
andglycemia.Diabetesisnotasimpledis-
ease, and its complications are complex,
but while microvascular disease is de-
monstrably related to glucose concentra-
tions, Roth termed the link of glycemia to
macrovasculardiseasedifﬁculttodemon-
strateand“reallymarginal,”sothatearlier
treatment initiation may delay the disease
process. Furthermore, given the rather
rapid shift that occurs from normal to
high levels of glucose (and insulin), Roth
suggested that the rapidity of change in
these measures be taken into account in
determining which patients with early
disease require treatment and argued
somewhat against the use of insulin in
early diabetes treatment, endeavoring in-
stead to “get at this much earlier” to re-
duce adverse outcome.
Insulin secretory dysfunction and IR
Kristina Utzschneider (Seattle, WA) dis-
cussed the role of -cell dysfunction in
glucose metabolism, pointing out that in
type 2 diabetes IR is accompanied by
-cell dysfunction with -cell apoptosis
and subsequent loss of compensation (4).
It has long been recognized that -cell
mass is decreased in type 2 diabetes (5),
while obesity increases -cell volume (6).
Both impaired fasting glucose and type 2
diabetesareassociatedwithnormal-cell
replication rates but increased apoptosis.
Reduction in -cell mass is not, however,
sufﬁcient to explain the insulin secretory
defectintype2diabetes,withevidenceas
well of a -cell functional defect in the
loss of acute insulin response (AIR) to in-
travenous glucose beginning at fasting
glucose levels around 115 mg/dl (7), with
the insulin response to oral glucose de-
pendent on insulin sensitivity (8). If type
2 diabetes is, then, characterized by both
IR and -cell dysfunction, the latter
may be relevant to identifying patients at
risk and to evaluating the effects of
interventions.
There is a hyperbolic relationship be-
tween the acute insulin secretory re-
sponse to glucose and insulin sensitivity
(9). Superimposed on this is a decline in
-cell function with increasing fasting
glucose and worsening glucose tolerance
levels(10)—apatternalsoseeninpersons
at risk of type 2 diabetes, such as relatives
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with PCOS, women who have had gesta-
tional diabetes mellitus, and older indi-
viduals; an example of this is a study of
Pima Indians over time, with persons de-
teriorating from normal to impaired glu-
cose tolerance to type 2 diabetes having
progressive decrease in the hyperbolic re-
lationship between insulin secretion and
insulin sensitivity (11). Utzschneider ex-
amined the differences in effect of differ-
ent interventions, reviewing a 6-month
program of exercise training that im-
proved insulin sensitivity without im-
provementin-cellfunction,theeffectof
troglitazone in improving both -cell
function and insulin sensitivity, and the
effect of administration of nicotinic acid
for 2 weeks in worsening -cell function.
Similarinformation,althoughwithsome-
what less precision, can be obtained from
analysis of insulin and glucose patterns
following oral glucose. Measuring the
change from time 0 to 30 min in insulin
versus glucose (I/G30), indicative of
insulin secretion adjusted for blood glu-
cose, and the reciprocal of the fasting in-
sulinasameasureofIR,therelationshipis
again hyperbolic, with deterioration from
normal to impaired glucose tolerance/
impaired fasting glucose to type 2 diabe-
tes (12). Utzschneider referred to the
constant of the hyperbolic relationship,
the product 1/[fasting insulin] multiplied
byI/G30,astheoraldispositionindex.
Asthedispositionindexworsensthelike-
lihoodofdiabetesincreases,withreceiver
operating characteristic analysis suggest-
ingthistobeabetterpredictorthaneither
1/fasting insulin or I/G30 alone. A
number of other studies have shown the
usefulness of these approaches; the inci-
dence of diabetes was related to 1/[fasting
insulin]inananalysisoftheDiabetesPre-
vention Program (13).
Is insulin secretion reduced in
type 2 diabetes?
Gerald Reaven (Stanford, CA) discussed
approaches to measurement of insulin se-
cretoryfunctionintype2diabetestosup-
port his concept that the -cell plays a
secondaryroleinthepathogenesisoftype
2 diabetes, with the notion of its being
similar in importance to IR based on in-
correct assessment methodologies (14).
Theconventionalwisdom,heopined,has
been that type 2 diabetes is characterized
by progressive and inexorable loss of
-cell function. If one measures glucose
and insulin levels through the day in per-
sons with varying levels of glycemia, he
said, it is remarkable that “the -cell is far
from dead” even as diabetes advances,
with insulin levels similar to those in eu-
glycemic persons, particularly during the
overnight period, although with glucose
and free fatty acid levels considerably
higher, conﬁrming IR.
Anumberofmethodshavebeenused
in assessing insulin secretion, such as ho-
meostasis model assessment of -cell
function (HOMA-B) (fasting insulin 
20/[fasting glucose  3.5]); AIR during
the initial 5 min following a 20-g intrave-
nous glucose load; an oral glucose toler-
ance test to deﬁne the changes in glucose
and insulin at 30 min after 75-g oral glu-
cose, typically calculated as I/G30-min;
the hyperglycemic clamp, measuring the
insulinsecretoryresponsetoagivenﬁxed
level of glycemia; and the meal tolerance
test, measuring glucose and insulin in re-
sponses to mixed meal. Reaven discussed
four confounding issues: glucose toxicity,
the effect of hyperglycemia on the -cell,
the effect of varying glucose loads
(whether coexisting plasma glucose and
insulin concentrations are constant in
their relationship and physiologically
meaningful), and the reliance on fasting
glucose and insulin levels.
Glucose toxicity is an important con-
sideration in the argument against the
concept that type 2 diabetes per se is as-
sociated with insulin deﬁciency. AIR to
glucose is essentially absent in persons
with fasting plasma glucose (FPG) 115
mg/dl and is decreased markedly with
FPG 100 mg/dl (15). Furthermore,
when FPG is 126 mg/dl, AIR is no
longer related to FPG and drops nearly to
0 (16), leading Reaven to state that “AIR
has limited ability to quantify -cell func-
tion at hyperglycemic states.” Given the
decreasedinsulinresponsetohyperglyce-
mia with oral glucose, Reaven asked
whether this is reﬂected in the insulin se-
cretory response to meals and showed
data suggesting that this is not the case,
althoughherecognizedthatonecouldar-
gue “insulin levels should be much
higher” because of hyperglycemia.
The confounding effect of glucose
load is an interesting subtlety which
Reaven noted, pointing out that the
amountofglucosethatmustbeinfusedto
reach a given level of hyperglycemia var-
ies with baseline glucose and with insulin
sensitivity. To compare -cell function,
one must then assume that differences in
absolute glucose load have no effect on
the amount of insulin secreted. In animal
models, however, Reaven showed evi-
dencethatthisisnotthecase,withgreater
and lesser glucose infusions achieving
similar plasma glucose levels leaving to
higher and lower insulin levels, respec-
tively. [Note: This consideration may also
be relevant to the classic studies of the
“incretin effect,” as the glucose load given
orally exceeds that given intravenously to
achieve similar blood glucose levels, and
increasinginsulinsecretoryresponsescan
be demonstrated with similar plasma glu-
cose levels in response to increasing oral
glucose loads (17).]
Reaven also discussed issues pertain-
ing to the notion of I/G, pointing out
that this ratio assumes that the insulin re-
sponse is a linear function of the plasma
glucose and also that the plasma glucose
is the sole determinant of the plasma in-
sulin response, which is certainly not the
case, as has been demonstrated in studies
oftheincretineffectshowingthatoralnu-
trient increases the insulin response to a
given plasma glucose. Reaven reviewed a
study of healthy volunteers who were
given 20 or 40 g glucose/m
2 body surface
area, with glucose levels similar but insu-
lin responses quite different. Further-
more, I/G may vary considerably
when successive glucose tolerance tests
are performed. Assumptions about the
linear response of insulin to glucose may
explain the much lower level of HOMA-B
in type 2 diabetes than in persons with
normal glucose tolerance, as the insulin
levels of the former are not particularly
low and the differences are driven by dif-
fering fasting glucose levels.
How inexorable, Reaven asked, is the
loss of insulin secretion in type 2 diabe-
tes? He discussed a study of a very low-
calorie diet, during which day-long
glycemia improved and -cell function
normalized. Another study of long-
standing type 2 diabetic Pima Indians
showed that 4 weeks of intensive dietary
treatment to achieve euglycemia led to
improved -cell function (18). Similarly,
a study comparing persons with normal
versus impaired glucose tolerance
showed that insulin sensitivity was lower
in the latter, fasting glucose higher, fast-
ing insulin higher, and HOMA-B lower,
but total insulin secretion after a test meal
was higher, which Reaven described as a
“total disconnect” of HOMA-B from other
measures of insulin secretion. Indeed,
HOMA-B decreased with but total pran-
dial insulin secretion increased with in-
creasing FPG. If one compares the lower,
middle, and higher tertile of FPG, fasting
insulin and insulin secretion during the
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Although the steady-state plasma glucose
(SSPG), a measure of IR, correlated both
with HOMA-B and with meal-related
insulin secretion, the latter relationship
was much stronger, suggesting that with
decreased insulin sensitivity the -cell
does behave appropriately. Reaven con-
cluded that insulin secretion estimates
vary with the method used and that it is
not clear that -cell function progres-
sivelyfailswiththedevelopmentoftype2
diabetes.
IR in brain aging and dementia
SuzanneCraft(Seattle,WA)discussedthe
role of IR in brain aging and dementia.
Insulin is a feeding and satiety signal, in-
volved in normal brain function and cog-
nition,withdysregulationofinsulin(both
IR and hyperinsulinemia) increasing the
risk for cognitive impairment, Alzhei-
mer’s disease (AD), and other neurode-
generative diseases. The insulin receptor
ispresentinneuronalelementsofthehip-
pocampusandentorhinalandfrontalcor-
tex, and insulin crosses the blood brain
barrieratphysiologiclevelsviaatransport
system, with controversy as to whether
insulin is also synthesized in areas of the
brain. Insulin increases levels of neuro-
transmitters such as acetyl choline and
norepinephrine and modulates glucose
metabolism in the hippocampus, increas-
ing neuronal ﬁring, which enhances
memory at optimal doses.
IR, hyperinsulinemia, and impaired
glucose tolerance and type 2 diabetes are
associated with increased AD risk and
memory impairment in epidemiologic
studies, with possible mechanisms in-
cluding impaired cerebral glucose me-
tabolism, disrupted -amyloid (A)
trafﬁcking and clearance and abnormal
regulationofotherkeyproteins,impaired
synaptic maintenance, increased inﬂam-
mation, impaired vascular function, and
prolonged hyperinsulinemia reducing
brain insulin transport, decreasing brain
insulin uptake and signaling. AD is the
mostcommonformofdementia,affecting
six million people in the U.S., with expo-
nential increase in prevalence with age,
deﬁned by deﬁcits in memory as well as
one or more other area of cognition. The
ﬁrstpathologicﬁndingislossofsynapses,
with subsequent loss of neurons leading
to atrophy and cerebral volume loss. His-
tology shows neuroﬁbrillary tangles of
hyperphosphorylated tau and neuritic
plaques composed of aggregated A.
Positron emission tomography shows ab-
normal brain glucose metabolism in non-
demented adults with hyperglycemia. AD
showsapatternofhypometabolisminthe
frontal and temporoparietal cortex and
theposteriorcingulatearea,apatternalso
seen in persons with IR, implying that “IR
creates a vulnerability in cerebral glucose
metabolism that may increase the risk of
developing AD over time.” A peptide
oligomers may have neurotoxic and
memory-inhibiting effects, even prior to
its aggregation into plaques. Insulin reg-
ulates A levels by promoting its intracel-
lular release from neurons, and insulin-
degrading enzyme degrades A as well,
further suggesting important interaction,
whereby insulin and A exert reciprocal
effects in regulating each others’ metabo-
lism,withApotentiallyworseningbrain
IR, while, conversely, insulin can protect
A-induced toxic effects on synapses,
although in animal models peripheral IR
increases brain A burden and im-
pairs memory. In a hyperinsulinemic-
euglycemic clamp human study, there
was an age-related increase in spinal ﬂuid
A, with insulin infusion also increasing
spinal ﬂuid interleukin (IL)-1b, IL-6, and
tumor necrosis factor-, as well as in-
creasingF2-isoprostane,amarkeroflipid
peroxidation and inﬂammation and oxi-
dative stress. Lipid infusion caused IR
with increased spinal ﬂuid A, further
implying a reciprocal relationship be-
tween insulin and A, with such changes
in A associated with markers of inﬂam-
mation and oxidative stress.
Another important component of AD
is reduced brain insulin uptake and sig-
naling, with low levels of spinal ﬂuid and
brain insulin. Insulin treatment reduces
brain atrophy in AD models, although
raising peripheral insulin levels would
not be expected to beneﬁt. Craft’s group
has studied intranasal insulin administra-
tion, as this route bypasses the blood
brain barrier by following the olefactory
and trigeminal nerves to rapidly reach the
brain (19). Intranasal insulin in humans
appears to improve memory in early AD.
IntheStudyofNasalInsulintoFightFor-
getfulness (SNIFF), intranasal insulin (20
units twice daily) improved memory, al-
though it did not change fasting or post-
prandial glucose or insulin; a larger
clinical trial is underway. Insulin sensiti-
zation may also be beneﬁcial, with both
pioglitazone and rosiglitazone suggesting
beneﬁt, and a 6-month intensive aerobic
(versus stretching) exercise intervention
enhancedcognition.Caloricrestrictionin
primates beginning in midlife improved
insulin sensitivity, cognition, and overall
health (with lessening of gray hair, lead-
ing to great enthusiasm in the audience!)
(20).
Not all dementia in older individu-
als with diabetes reﬂects AD. An au-
topsy study comparing people with and
without diabetes and with and without
AD showed highest A in people with
dementia who did not have diabetes,
perhaps from diabetic patients with de-
mentia having greater risk of cerebro-
vascular disease. There was also an
association of microvascular lesions
with dementia in the diabetic group,
perhaps as markers of vascular pathol-
ogy or by a direct role, with such ﬁnd-
ingsandlowerlevelsofamyloidplaques
particularly in demented diabetic pa-
tients who were treated with insulin.
Antipsychotic drugs and IR
Sun Kim (Stanford, CA) discussed effects
ofantipsychoticmedicationsonIRandon
insulin secretion. She noted that lipid-
lowering medication is the ﬁrst, proton
pump inhibitors are the second, and an-
tipsychotic medication is the third in
ranking by dollar volume of drugs sold in
the U.S., implying very wide use of the
latter, not only for schizophrenia but also
for bipolar states, dementia, psychotic
depression, autism, developmental disor-
ders, and adolescent conduct disorders.
Individuals with mental health disorders
have a two- to threefold increase in
risk for diabetes, cardiovascular (CV) dis-
ease, and death, leading to concern as
to whether the obesity- and diabetes-
causing effects of antipsychotic agents
may be mediators. Mental illness is itself
associated with obesity, with mediators
including increased caloric intake, de-
creased activity, “stress,” and genetic pre-
disposition, but the weight-increasing
effect of medications as well. Prior to the
widespread use of second-generation an-
tipsychotics, the weight of persons with
schizophreniawassomewhatgreaterthan
that in the reference population. The U.S.
is, Kim stated, the most obese country in
the world, with 30% of the population
having BMI 30 kg/m
2, but 47% of peo-
ple with schizophrenia have BMI above
this level, and similar associations of
schizophrenia with obesity are seen in
other countries. The prevalence of meta-
bolic syndrome among people with
schizophrenia was 36.6% in men and
54.2%inwomen(21),farabovethelevels
of 25.1% and 19.7%, respectively, in the
overall U.S. population.
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ated with the greatest degree of weight
gain, risperidone and quetiapine are in-
termediate, and aripiprazole and ziprasi-
done lead to the lowest amounts; a recent
study showed similar effects of these
agents on weight gain in children and ad-
olescents(22).Olanzapinemayalsocause
a greater degree of IR than that attribut-
able to the weight gain alone (23). Kim
reviewed a study that compared 54 sub-
jectstreatedwitholanzapine,risperidone,
or aripiprazole with a control population
and showed that one-quarter of the vari-
ance in IR was explained by the degree of
obesity in both groups, suggesting overall
similarity of these agents, although there
was a trend to a greater reduction in insu-
lin sensitivity for a given BMI among sub-
jects receiving olanzapine.
The question also has been raised as
to whether there are direct effects of sec-
ond generation antipsychotics on insulin
secretion.Inanimalmodels,thereissome
suchevidence,butKimsuggestedthatlit-
tle supporting evidence of decreased
insulin secretion can be demonstrated
in human studies; her study of olanzap-
ine, risperidone, and aripiprazole during
a graded increasing glucose infusion
over 4 h showed the highest glucose-
stimulated insulin secretion rate with
olanzapine, a similar level with aripipra-
zole, and a lower level with risperidone,
with glucose-stimulated insulin secretion
corrected for SSPG similar with the three
drugs, suggesting that the weight-
increasing effect of the drugs is responsi-
ble for their metabolic effects. Most
studies show the second-generation anti-
psychotics to have greater diabetes-
causing effect than ﬁrst-generation agents
such as chlorpromazine and haloperidol
(24). American Diabetes Association
(ADA) guidelines suggest regularly
checking weight, lipids, and blood glu-
cose in patients receiving these medica-
tions (25), although adherence to such
screening has been limited, with only ap-
proximately one-quarter of patients
having glucose and one-tenth lipid mea-
surements, which Kim considered rather
worrisome (26).
Initial approaches to treatment are,
Kim suggested, lifestyle modiﬁcation,
metformin, perhaps pioglitazone, and
lipid and blood pressure treatment. Kim
reviewed a pilot study her group had un-
dertaken, in which 15 persons who had
gained 10 kg on prior antipsychotic
treatment were given aripiprazole (27).
Of the group, ﬁve could not tolerate the
agent,threelostsomeweight(butshowed
little change in insulin sensitivity), and
the remainder showed little change in ei-
therparameter.Arecentstudyof173per-
sons randomized to continuing
olanzapine or changing to aripiprazole
showed that 26 vs. 36% dropped out,
suggesting the former to be better psychi-
atrically, although weight and tri-
glycerides levels did improve (28).
Clearly, this is a complex topic, and the
treating physician needs to weight risks
and beneﬁts of the various agents.
IR in adolescence
Alan Sinaiko (Minneapolis, MN) dis-
cussed the role of IR in development of
CV risk in adolescents. He pointed out
that insulin sensitivity measures based on
fasting insulin and glucose such as
HOMA-IR (fasting insulin  fasting glu-
cose/22.5) are driven more by the nearly
100-foldrangeoffastinginsulin(from1.5
to 79.6 pmol/l) than by the 2-fold nondi-
abetic range of fasting glucose (from 3.5
to 6.5 mM/l), explaining the close corre-
lation between fasting insulin and
HOMA-IR in nondiabetic children. The
correlations of fasting insulin or of
HOMA-IR with IR as measured from eu-
glycemic-hyperinsulinemic clamps are
low, with Pearson correlation coefﬁcient
0.4 (29), and the correlation is even
worse in lean children, leading to Sinaiko
to suggest that the usefulness of the insu-
lin level in distinguishing the degree of
insulinsensitivityinanindividualchildis
limited.Hereviewedthepatternsofwors-
ening insulin sensitivity leading to in-
creases in blood pressure and worse lipid
levels during adolescence in boys,
whereasallparameterstendtoimprovein
girls, with discordance in consequent CV
risk. IR at age 13 years predicts blood
pressure and triglyceride abnormalities at
age 19 years (30). Fasting insulin levels,
however, become similar during adoles-
cence in the two sexes, and body fat in-
creases in girls and decreases in boys,
further suggesting this not to be particu-
larly useful in assessing insulin sensitivity
(31). Obesity appears to be the factor that
best predicts which children will develop
into adults with coronary artery disease
(CAD) risk and subsequent CAD events.
The presence of IR adds signiﬁcantly to
CV risk in obese but not in lean adoles-
cents,andmetabolicsyndromeappearsto
be a good predictor of future CV risk.
Julia Steinberger (Minneapolis, MN)
discussed the development of IR in survi-
vorsofchildhoodcancer.Themortalityof
childhood cancers has decreased over the
past 3–4 decades, with estimated cure
rates now more than 85%, although the
incidence of childhood cancers has in-
creased. Currently 1 of every 900 young
adults is a survivor of a childhood cancer,
with myriad consequences affecting the
endocrine, cardiac, pulmonary, renal/
urologic, gastrointestinal/hepatic, and
neurologic/psychiatric systems, as well as
increased likelihood of a second malig-
nancy. Chemotherapy, radiation, and
surgery all have the potential to produce
vascular, musculoskeletal, and nerve
damage. Growth issues often are caused
by radiotherapy directed to the brain or
spinal cord, leading to hypothalamic/
pituitary damage. Myocardial infarction
and stroke appear to increase in limited
studies, with a 10-fold increase in late
mortality, caused by cancer relapse, most
commonly from subsequent malignancy,
but with cardiac disease the next most
likely cause (32). Hypercholesterolemia,
hypertension, obesity, and hyperinsulin-
emia are seen with increased prevalence.
InSteinberger’sstudyofsurvivorsofbone
marrow transplantation, there were 3.7-
and 2.1-fold increases in rates of diabetes
and hypertension, respectively, with 3.5-
fold increase in stroke risk and 1.2-fold
increase in myocardial infarction, not as-
sociated with obesity. High triglyceride,
low HDL, and IR were found, and one-
third of trial participants had evidence of
growth hormone (GH) deﬁciency, not
only related to radiation treatment. The
group was shorter, with lower IGF-1,
greater adiposity, and higher triglyceride
levels, although no differences were
found in blood pressure, HDL choles-
terol, or fasting glucose levels. GH ther-
apy appeared to somewhat ameliorate the
abnormalities, and the degree of meta-
bolic abnormality appeared to be propor-
tionate to the degree of reduction in GH
secretion, so that consideration is being
given to a study of GH replacement, but a
number of oncologists have raised the
concern that this could cause develop-
ment of second malignancies.
PCOS
John Nestler (Richmond, VA) discussed
the role of IR in PCOS, and the rationale
for use of insulin sensitizers in women
with PCOS who have normal insulin sen-
sitivity. PCOS is a disorder deﬁned by
having at least two of chronic oligo/
anovulation and/or hyperandrogenism
and/or PCO on ultrasound (with exclu-
sion of congenital adrenal hyperplasia,
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a variety of other causes of hyperandro-
genism), affecting 6–10% of women of
childbearing age. Hyperinsulinemic IR
appears to be a characteristic of women
with PCOS when compared with similar
weight women who have normal ovula-
tion; an obese woman with PCOS has a
degree of IR similar to one with type 2
diabetes (33).
In opposite-sex twin pairs, intrauter-
ine exposure to androgens may contrib-
ute to development of PCOS, and studies
of androgen administration in utero to fe-
male rhesus monkeys, particularly early
in pregnancy, show subsequent develop-
mentofaPCOSphenotype.Nestler,how-
ever, presented data from a Netherlands
registry of 1,325 monozygotic and 1,191
dizygotic twins, with 711 female subjects
from same-sex and 480 female subjects
from opposite-sex twin pairs, not show-
ing such an association (34). It may be,
then,thatandrogensdonotactdirectlyin
thefetus,butratherthatmetabolicdistur-
bances induced by androgens in the
mother program the developing fetus
for PCOS. In a study of 30 prepubertal
and69pubertalgirlsborntowomenwith
PCOS, compared with 20 and 64, respec-
tively, born to normal women and
with similar age and BMI, insulin, glu-
cose, lipid, luteinizing hormone, 17-
hydroxyprogesterone, and testosterone
were higher in Tanner stages IV and V
PCOS daughters, but ovarian volume and
the 2-h insulin were higher in PCOS
daughtersthroughallpubertystages(35),
implying that PCOS daughters show
features of the syndrome and hyperinsu-
linemia prior to the development of an-
drogen abnormalities. PCOS penetrance
was high, 45 and 60% at Tanner stages IV
and V, respectively.
Nestler pointed out that most women
with PCOS are obese and hence will be
certain to have IR and that there is no
simple method to determine insulin sen-
sitivity in an ofﬁce setting, so that he felt
the correct question is whether any vari-
able predicts whether a woman will or
will not respond to insulin sensitizer
treatment. In a study of 128 nonobese
women with PCOS, with fasting insulin
15 	IU/ml, metformin did induce ovu-
lation although requiring 6 months to
show effect (36). Nestler suggested that
the ﬁnding could be interpreted to show
that these women did actually have IR, or
that metformin directly inhibited ovarian
androgen biosynthesis, or, perhaps, that
PCOS is characterized in some women by
ovarianhypersensitivitytoinsulin,imply-
ing that a threshold may exist, varying
from woman to woman based on IR
(whether intrinsic or related to obesity)
and ovarian sensitivity to insulin, so that
women with a low such threshold could
exhibit a PCOS phenotype.
David Abbott (Madison, WI) gave a
different view of the developmental ori-
gins of IR and -cell defects based on a
nonhumanprimatemodelforPCOS(37).
His group hypothesized that the PCOS
ovary develops as an overproducer of an-
drogens regulating ovarian follicle devel-
opment and steroid synthesis, with
consequent effect on genes regulating in-
sulin secretion and action and adipocyte
differentiation. In their study, pregnant
nonobese rhesus monkey females were
administeredtestosteronefromdays40to
80 of the typical 170-day gestation, with
testosterone levels increasing from 0.03
to 0.3–0.4 ng/ml. The adult female off-
spring had oligomenorrhea, an increased
testosteroneresponsetohumanchorionic
gonadotropin, and 40% had polycystic
ovaries.Theyhadincreasedabdominalfat
with no difference in total body fat mass,
and free fatty acid levels were higher dur-
ing an intravenous glucose tolerance test
(38). Insulin sensitivity and disposition
index were lower; pancreatic islet histol-
ogy showed decreased insulin staining,
suggesting decreased -cell mass; and
27.3% developed type 2 diabetes, com-
pared with no controls. In the neonate,
there was androgenization of external
genitalia. Abbott pointed out that the
model was imperfect, as there was greater
maternal weight gain and glucose intoler-
ance during pregnancy after testosterone
administration. Furthermore, fetal glu-
cose at gestational day 80 correlated neg-
atively with serum glucose immediately
after birth suggesting maternal hyperin-
sulinism, and there was somewhat in-
creased weight of treated infants after
birth, with a 75% increase in insulin
staining in islets of the offspring of testos-
terone-treated mothers. One cannot,
then, clearly distinguish exogenous an-
drogen-induced mild-moderate maternal
glucose intolerance causing hyperglyce-
mia that increases fetal growth from fetal
androgen excess as the cause of the PCOS
phenotype—showing the complexity of
therelationshipbetweenIRandabnormal
androgen status.
David Ehrmann (Chicago, IL) dis-
cussed a potential effect of sleep apnea
as a contributory factor to PCOS. Given
the high prevalence of obstructive sleep
apnea (OSA) in people with obesity, hy-
perinsulinemia, and, perhaps, hyperan-
drogenemia, it is reasonable to assume
that PCOS would be associated with
this condition. OSA is characterized by
frequent microarousals and reductions
in slow-wave sleep and is associated
with glucose intolerance and IR. In a
study of three nights of sleep disruption
during stage 3–4 sleep in normal-
weight men and women, glucose toler-
ance and insulin sensitivity decreased
(39). OSA can cause sympathetic ner-
vous system overactivity, hypertension,
glucose intolerance, and dyslipidemia.
Overnight polysomnography of 18
obese women with PCOS and age/
weight-matched control subjects
showed OSA in 44 and 5%, respectively
(40). Ehrmann’s study showed OSA to
be 7.1-fold more common in women
withPCOSthanincontrolsubjects,and
the severity of OSA correlated with fast-
ing insulin and fasting and 2-h glucose
levels.Althoughandrogenlevelsdidnot
correlate with the degree of OSA, low
estrogen and progesterone were not ex-
cluded as contributory factors (41).
Continuous positive airway pressure
treatment improves sympathetic hyper-
activity and insulin sensitivity both in
lean and in obese women.
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